The lancet. Gastroenterology & hepatology
-
Lancet Gastroenterol Hepatol · Dec 2020
Randomized Controlled Trial Multicenter StudyCobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
Cobitolimod is a topically administered, DNA-based oligonucleotide that activates Toll-like receptor 9 (TLR9), and previous research has shown clinical efficacy in patients with moderate-to-severe ulcerative colitis. Here we assessed the efficacy and safety of different dose regimens of cobitolimod for induction therapy in patients with moderate-to-severe, left-sided ulcerative colitis. ⋯ InDex Pharmaceuticals.
-
Lancet Gastroenterol Hepatol · Nov 2020
Multicenter StudyOutcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.
Despite concerns that patients with liver transplants might be at increased risk of adverse outcomes from COVID-19 because of coexisting comorbidities and use of immunosuppressants, the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on this patient group remains unclear. We aimed to assess the clinical outcomes in these patients. ⋯ European Association for the Study of the Liver, US National Institutes of Health, UK National Institute for Health Research.